目的观察丁苯肽联合通心络治疗急性期脑梗死的临床效果及安全性。方法收集该院2010年4月-2013年9月诊治的急性期脑梗死患者120例,随机分为试验组与对照组各60例。2组均应用抗血小板和改善脑血液循环药物等常规治疗。在此基础上,对照组单纯采用通心络胶囊治疗,试验组在对照组的基础上加用丁苯肽软胶囊治疗。比较2组患者的临床疗效、神经功能缺损评分和日常生活能力评分,并观察2组不良反应发生情况。结果治疗后试验组的总有效率为95.0%高于对照组的85.0%;治疗后2组患者的ESS评分和Barthel评分均高于治疗前,且试验组高于对照组,差异均有统计学意义(P<0.05)。2组患者治疗过程中均未出现严重不良反应。结论丁苯肽联合通心络治疗急性期脑梗死效果较好,可显著改善患者神经功能及日常生活能力,不良反应少,值得临床推广应用。 Objective To observe the clinical effect and safety of butadiene combined with Tongxinluo in the treatment of acute cerebral infarction. Methods A total of 120 acute cerebral infarction patients diagnosed and treated in our hospital from April 2010 to September 2013 were randomly divided into experimental group and control group of 60 cases. Both groups were given antiplatelet and drugs such as cerebral blood circulation to improve the routine treatment. On this basis, the control group was treated with Tongxinluo capsule only, and the experimental group was treated with the soft capsule of butanlin based on the control group. The clinical efficacy, neurological deficit score and daily living ability score of two groups were compared, and the occurrence of adverse reactions in two groups were observed. Results After treatment, the total effective rate of the experimental group was 95.0%, which was higher than that of the control group (85.0%). ESS score and Barthel score of the two groups after treatment were higher than those before treatment, and the experimental group was higher than the control group Significance (P <0.05). No serious adverse reactions occurred in the two groups during the course of treatment. Conclusion DBT combined with Tongxinluo in the treatment of acute cerebral infarction is better, which can significantly improve the patient’s neurological function and daily living ability with fewer adverse reactions, which is worthy of clinical application.